MedPath

Evaluation of the Efficacy of Prophylactic Topical Gentamicin in Tunnelled Catheters for Hemodialysis

Phase 1
Completed
Conditions
Hemodialysis Catheter Infection
Interventions
Registration Number
NCT04967859
Lead Sponsor
Universidade Estadual Paulista Júlio de Mesquita Filho
Brief Summary

Chronic kidney disease (CKD) is a major public health problem worldwide, with a significant increase in the number of patients treated with dialysis and renal transplantation. Hemodialysis (HD) is the most widely used dialysis therapy in the world, and adequate vascular access is required. The central venous catheter (CVC), although not considered the ideal vascular access, is still widely used. Its use has a strong relation with access-related infection, whether it is an exit orifice (IES), a tunnel and the most severe, the bloodstream (BSI). Consequently CVC contributes to patients' morbidity and mortality in HD, as well as to the high cost of hemodialysis treatment.

To compare the use of 0.1% topical gentamicin with the use of placebo in the exit site (ES) of tunneled catheters in patients in chronic HD regarding the reduction in IES and BSI rates and to identify the induction of bacterial resistance to gentamicin.

Detailed Description

A randomized, double-blind clinical trial comparing the use of 0.1% gentamicin versus placebo in the ES of tunnelled catheters for hemodialysis in the prevalence and density of incidence of IES and BSI. Patients will be allocated into two groups randomly: Group 1 (control): Patients using placebo ointment in ES; Group 2 (intervention): Patient using 0.1% gentamicin ointment in ES.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria

Not provided

Exclusion Criteria
  • patients under 18 years of age
  • pregnant women
  • other types of access for dialysis other than tunnelled catheters
  • course of infection at the time of initiation of the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group 1 (control):PlaceboPatients using placebo ointment at the exit site of the hemodialysis catheter
Group 2 (intervention)0.1% gentamicinPatient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter
Primary Outcome Measures
NameTimeMethod
Rates of exit-site infection1 years

Rates of exit-site infection (measured in events per 1,000 catheter-days)

Rates of catheter-related bloodstream infections1 years

Rates of catheter-related bloodstream infections (measured in events per 1,000 catheter-days)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Universidade Estadual Paulista Júlio de Mesquita Filho

🇧🇷

Botucatu, São Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath